Table 1.
Characteristics of the patients in the training and validation cohorts.
| Variable | Training cohort (n = 198) | Validation cohort (n = 145) | P value |
|---|---|---|---|
| BMI, no. (%) | |||
| ≥24 kg/m2 | 47 (23.7) | 37 (25.5) | 0.71 |
| <24 kg/m2 | 151 (76.3) | 108 (74.5) | |
| CEA, no. (%) | |||
| Elevated | 58 (29.3) | 39 (26.9) | 0.63 |
| Normal | 140 (70.7) | 106 (73.1) | |
| CA 19-9, no. (%) | |||
| Elevated | 48 (24.2) | 29 (20.0) | 0.35 |
| Normal | 150 (75.8) | 116 (80.0) | |
| Tumour location, no. (%) | |||
| Cardia of the stomach | 41 (20.7) | 44 (30.3) | 0.10 |
| Body of the stomach | 50 (25.3) | 36 (24.8) | |
| Antrum of the stomach | 107 (54.0) | 65 (44.9) | |
| Tumour size, no. (%) | |||
| ≥4 cm | 114 (57.6) | 93 (64.1) | 0.22 |
| <4 cm | 84 (42.4) | 52 (35.9) | |
| Lauren classification, no. (%) | |||
| Intestinal | 71 (35.9) | 61 (42.1) | 0.24 |
| Diffuse or mixed | 127 (64.1) | 84 (57.9) | |
| Differentiation status, no. (%) | |||
| Well | 11 (5.6) | 6 (4.1) | 0.33 |
| Moderate | 39 (19.7) | 40 (27.6) | |
| Poor | 95 (48.0) | 60 (41.4) | |
| Undifferentiated | 53 (26.7) | 39 (26.9) | |
| Lymph node metastasis, no. (%) | |||
| N0 | 52 (26.3) | 29 (20.0) | 0.13 |
| N1 | 45 (22.7) | 25 (17.2) | |
| N2 | 35 (17.7) | 40 (27.6) | |
| N3a | 38 (19.2) | 33 (22.8) | |
| N3b | 28 (14.1) | 18 (12.4) | |
| Chemotherapy, no. (%) | |||
| Yes | 144 (72.7) | 93 (64.1) | 0.09 |
| No | 54 (27.3) | 52 (35.9) | |
| Collagen signature, median (IQR) | 0.047 (−0.247 to 0.397) | 0.056 (−0.031 to 0.187) | 0.43 |
The comparison of collagen signature between two cohorts is performed using a two-sided Mann–Whitney U test, and the rest variables are compared using a two-sided χ2 or Fisher’s exact test.
BMI body mass index, CA carbohydrate antigen, CEA carcinoembryonic antigen, IQR interquartile range.